FDA.reportPublic FDA data

upadacitinib 1 MG per 1 ML Oral Solution

RxCUI
2681015
RxNorm name
upadacitinib 1 MG per 1 ML Oral Solution
Display name
upadacitinib 1 MG per 1 ML Oral Solution
Full name
upadacitinib 1 MG per 1 ML Oral Solution
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:51

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
RinvoqUPADACITINIBAbbVie Inc.2966aec7-2ef0-923c-d8ff-fe1a957bf0952026-06-30Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2681015

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
2966aec7-2ef0-923c-d8ff-fe1a957bf095upadacitinib 1 MG in 1 mL Oral Solution [PSN] · upadacitinib 1 MG/ML Oral Solution [SCD] · upadacitinib 1 MG per 1 ML Oral Solution [SY]3100These highlights do not include all the information needed to use RINVOQ / RINVOQ LQ safely and effectively. See full prescribing information for RINVOQ / RINVOQ LQ . RINVOQ ® (upadacitinib) extended-release tablets, for oral use RINVOQ ® LQ (upadacitinib) oral solution Initial U.S. Approval: 201920251023